Product class: Authorized package
Medicinal product class: Veterinary medicine
Package code: 1619164
Name of medicinal product: Oncept IL-2
Active substances:
Feline interleukin-2 recombinant canarypox virus
Estonian, English, Latin
ATC code: QL03AX90
Dosage form: lyophilisate and solvent for suspension for injection
Route of administration: subcutaneous use
Strengh:  
Amount in package: 1annus 6TK
Legal status for supply*: Subject to medicinal prescription
Class of active substance:  
Additional information: lahusti 1 ml
Indication: Immunotherapy to be used in addition to surgery and radiotherapy in cats with fibrosarcoma (2-5 cm diameter) without metastasis or lymph node involvement in order to reduce the risk of relapse and to increase the time to relapse (local recurrence or metastasis). This was demonstrated in a field trial over a period of 2 years.
Safety features: No
Summary of product characteristics (SPC):
Package information leaflet (PIL): EST
Labelling:  
Withdrawal time: Ei rakendata
Species: kass
Last imported to Estonia: Never imported to Estonia
Marketing authorization holder: Boehringer Ingelheim Vetmedica GmbH 
Marketing authorization number: EU/2/13/150 
Marketing authorization issued on: 07 May 2013 
Marketing authorization expires on: Unlimited 
Marketing authorization procedure type: Centralised 
Entry/Changing date: 19 December 2020
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription